SNPHY vs. VRT

Last updated Jun 3, 2026

SNPHY (Santen Pharmaceutical Co) and VRT (Vertiv Holdings Co.) are both stocks. SNPHY operates in Drug Manufacturers - General (Healthcare), while VRT operates in Electrical Equipment & Parts (Industrials). Over the past 5 years, SNPHY returned -2.79%/yr vs 67.37%/yr for VRT. At a 0.07 correlation, their price movements are largely independent.

Performance

SNPHY vs. VRT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Santen Pharmaceutical Co (SNPHY) and Vertiv Holdings Co. (VRT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SNPHY achieves a 8.93% return, which is significantly lower than VRT's 104.63% return.

SNPHY

• 1D: -4.79%
• 1M: 11.92%
• YTD: 8.93%
• 6M: 11.92%
• 1Y: -0.00%
• 3Y*: 8.08%
• 5Y*: -2.79%
• 10Y*: -2.70%

VRT

• 1D: -0.91%
• 1M: 0.14%
• YTD: 104.63%
• 6M: 85.33%
• 1Y: 195.39%
• 3Y*: 156.10%
• 5Y*: 67.37%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

SNPHY vs. VRT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
SNPHY Santen Pharmaceutical Co	8.93%	3.17%	3.67%	22.59%	-34.03%	-25.14%	-14.64%	33.33%	-14.55%
VRT Vertiv Holdings Co.	104.63%	42.80%	136.82%	251.81%	-45.25%	33.80%	69.36%	12.55%	-0.51%

Correlation

The correlation between SNPHY and VRT is 0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.10
Correlation (3Y) Calculated over the trailing 3-year period	-0.01
Correlation (5Y) Calculated over the trailing 5-year period	0.06
Correlation (All Time) Calculated using the full available price history since Jul 31, 2018	0.07

The correlation between SNPHY and VRT shifts across timeframes, from -0.01 (3 years) to 0.10 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap SNPHY : $3.66B VRT : $129.97B
EPS SNPHY : $114.09 VRT : $3.99
PE Ratio SNPHY : 0.10 VRT : 83.15
PEG Ratio SNPHY : 0.00 VRT : 0.36
PS Ratio SNPHY : 0.01 VRT : 11.95
PB Ratio SNPHY : 0.01 VRT : 30.62
Total Revenue (TTM) SNPHY : $295.63B VRT : $10.84B
Gross Profit (TTM) SNPHY : $165.41B VRT : $3.92B
EBITDA (TTM) SNPHY : $65.30B VRT : $2.35B

Return for Risk

SNPHY vs. VRT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SNPHY

SNPHY Risk / Return Rank: 40
SNPHY Sharpe Ratio Rank: 40
SNPHY Sortino Ratio Rank: 38
SNPHY Omega Ratio Rank: 36
SNPHY Calmar Ratio Rank: 42
SNPHY Martin Ratio Rank: 42

VRT

VRT Risk / Return Rank: 94
VRT Sharpe Ratio Rank: 96
VRT Sortino Ratio Rank: 93
VRT Omega Ratio Rank: 91
VRT Calmar Ratio Rank: 96
VRT Martin Ratio Rank: 96

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SNPHY vs. VRT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Santen Pharmaceutical Co (SNPHY) and Vertiv Holdings Co. (VRT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SNPHY	VRT	Difference
Sharpe ratio Return per unit of total volatility	-0.00	3.42	-3.42
Sortino ratio Return per unit of downside risk	0.35	3.75	-3.40
Omega ratio Gain probability vs. loss probability	1.04	1.47	-0.43
Calmar ratio Return relative to maximum drawdown	0.10	7.94	-7.84
Martin ratio Return relative to average drawdown	0.20	22.67	-22.47
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SNPHY vs. VRT - Sharpe Ratio Comparison

The current SNPHY Sharpe Ratio is -0.00, which is lower than the VRT Sharpe Ratio of 3.42. The chart below compares the historical Sharpe Ratios of SNPHY and VRT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	SNPHY	VRT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.00	3.42	-3.42
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.07	1.10	-1.17
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.07	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	1.04	-1.13

Drawdowns

SNPHY vs. VRT - Drawdown Comparison

The maximum SNPHY drawdown since its inception was -82.47%, which is greater than VRT's maximum drawdown of -71.24%. Use the drawdown chart below to compare losses from any high point for SNPHY and VRT.

Drawdown Indicators

	SNPHY	VRT	Difference
Max Drawdown Largest peak-to-trough decline	-82.47%	-71.24%	-11.23%
Max Drawdown (1Y) Largest decline over 1 year	-20.31%	-24.78%	+4.47%
Max Drawdown (3Y) Largest decline over 3 years	-31.88%	-61.28%	+29.40%
Max Drawdown (5Y) Largest decline over 5 years	-58.99%	-71.24%	+12.25%
Max Drawdown (10Y) Largest decline over 10 years	-69.08%	—	—
Current Drawdown Current decline from peak	-68.71%	-11.90%	-56.81%
Average Drawdown Average peak-to-trough decline	-51.26%	-16.22%	-35.04%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.28%	8.66%	+1.62%

Volatility

SNPHY vs. VRT - Volatility Comparison

Santen Pharmaceutical Co (SNPHY) and Vertiv Holdings Co. (VRT) have volatilities of 16.82% and 16.92%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SNPHY	VRT	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.82%	16.92%	-0.10%
Volatility (6M) Calculated over the trailing 6-month period	34.12%	44.82%	-10.70%
Volatility (1Y) Calculated over the trailing 1-year period	48.12%	57.51%	-9.39%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	42.12%	61.71%	-19.59%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	36.34%	54.58%	-18.24%

Dividends

SNPHY vs. VRT - Dividend Comparison

SNPHY has not paid dividends to shareholders, while VRT's dividend yield for the trailing twelve months is around 0.06%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
SNPHY Santen Pharmaceutical Co	0.00%	1.26%	1.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.74%	1.98%
VRT Vertiv Holdings Co.	0.06%	0.11%	0.10%	0.05%	0.07%	0.04%	0.05%	0.00%	0.00%	0.00%	0.00%

Financials

SNPHY vs. VRT - Profitability Comparison

The chart below illustrates the profitability comparison between Santen Pharmaceutical Co and Vertiv Holdings Co. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

SNPHY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Santen Pharmaceutical Co reported a gross profit of 50.58B and revenue of 82.35B. Therefore, the gross margin over that period was 61.4%.

VRT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Vertiv Holdings Co. reported a gross profit of 999.70M and revenue of 2.65B. Therefore, the gross margin over that period was 37.7%.

SNPHY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Santen Pharmaceutical Co reported an operating income of 17.39B and revenue of 82.35B, resulting in an operating margin of 21.1%.

VRT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Vertiv Holdings Co. reported an operating income of 440.10M and revenue of 2.65B, resulting in an operating margin of 16.6%.

SNPHY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Santen Pharmaceutical Co reported a net income of 15.83B and revenue of 82.35B, resulting in a net margin of 19.2%.

VRT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Vertiv Holdings Co. reported a net income of 390.10M and revenue of 2.65B, resulting in a net margin of 14.7%.

Frequently Asked Questions

Can I hold both SNPHY and VRT in my portfolio?

SNPHY and VRT have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SNPHY or VRT?

VRT has higher volatility (16.92%) compared to SNPHY (16.82%). In terms of maximum drawdown, SNPHY dropped -82.47% vs VRT's -71.24%.

Which has better risk-adjusted returns?

VRT currently has the higher Sharpe Ratio (3.42 vs -0.00), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.